Browse > Article

Receptor-Ligand Binding Characteristics of KR-31064  

Lee, Sunghou (Dept. of Biomedical Technology, Sangmyung University)
Publication Information
YAKHAK HOEJI / v.58, no.1, 2014 , pp. 16-20 More about this Journal
Abstract
KR-31064 was developed for the strong angiotensin II receptor antagonist among the one of pyridyl imidazol series compounds. To investigate the receptor-ligand binding characteristics of this nonpeptide antagonist, binding experiments were deployed in various conditions and ex vivo contractile responses were tested toward the standard compound, losartan. Receptor binding experiments with radiolabeled angiotensin II, the $IC_{50}$ value for KR-31064 resulted 0.67 nM without any activities toward type 2 angiotensin II receptor. The comparative potency against losartan was more than 18 fold and the specific activity in type 1 angiotensin II receptor was more than 10,000 fold comparing to the type 2 receptor. Scatchard analysis of saturation binding data showed KR-31064 acted on the receptor in a competitive mode. KR-31064 inhibited the contractile response derived by angiotensin II ($pK_B$: 9.86) similar to that of losartan with decreased maximum signals. As a potent and specific type 1 angiotensin II receptor antagonist, KR-31064 may have possibilities for the development of diagnostic ligands that can be used as tools for various biochemical research experiments and non-invasive diagnostics.
Keywords
KR-31064; angiotensin receptor antagonist; antihypertension; receptor ligands; diagnostics; losartan;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Griendling, K. K., Lassegue, B., Murphy, T. J. and Alexander, R. W. : Angiotensin II receptor pharmacology. Adv. Pharmacol. 28, 269 (1994).   DOI
2 Wong, P. C., Price, W. A., Jr., Chiu, A. T., Duncia, J. V., Carini, D. J., Wexler, R. R., Johnson, A. L. and Timmermans, P. B. : In vivo pharmacology of DuP 753. Am. J. Hypertens. 4, 288S (1991).   DOI
3 Burnier, M. : Angiotensin II type 1 receptor blockers. Circulation 103, 904 (2001).   DOI   ScienceOn
4 Simpson, K. L. and McClellan, K. J. : Losartan: a review of its use, with special focus on elderly patients. Drugs & Aging 16, 227 (2000).   DOI
5 Iimori, H., Hashizume, Y., Sasaki, M., Kajiwara, Y., Sugimoto, Y., Sugiyama, Y., Watanabe, Y. and Senda, M. : First automatic radiosynthesis of 11C labeled Telmisartan using a multipurpose synthesizer for clinical research use. Ann. Nucl. Med. 25, 333 (2011).   DOI   ScienceOn
6 Mathews, W. B., Yoo, S. E., Lee, S. H., Scheffel, U., Rauseo, P. A., Zober, T. G., Gocco, G., Sandberg, K., Ravert, H. T., Dannals, R. F. and Szabo, Z. : A novel radioligand for imaging the AT1 angiotensin receptor with PET. Nucl. Med. Biol. 31, 571 (2004).   DOI   ScienceOn
7 Shimizu, K., Takashima, T., Yamane, T., Sasaki, M., Kageyama, H., Hashizume, Y., Maeda, K., Sugiyama, Y., Watanabe, Y. and Senda, M. : Whole-body distribution and radiation dosimetry of [11C]telmisartan as a biomarker for hepatic organic anion transporting polypeptide (OATP) 1B3. Nucl. Med. Biol. 39, 847 (2012).   DOI   ScienceOn
8 Xia, J., Seckin, E., Xiang, Y., Vranesic, M., Mathews, W. B., Hong, K., Bluemke, D. A., Lerman, L. O. and Szabo, Z. : Positron-emission tomography imaging of the angiotensin II subtype 1 receptor in swine renal artery stenosis. Hypertension 51, 466 (2008).   DOI   ScienceOn
9 Han, J., Park, S. J., Thu, V. T., Lee, S. R., Long, L. T., Kim, H. K., Kim, N., Park, S. W., Jeon, E. S., Kim, E. J., Yoon, C. H., Cho, G. Y. and Choi, D. J. : Effects of the novel angiotensin II receptor type I antagonist, fimasartan on myocardial ischemia/ reperfusion injury. Intl. J. of Cardiol. 168, 2851 (2013).   DOI   ScienceOn
10 Timmermans, P. B., Wong, P. C., Chiu, A. T., Herblin, W. F., Benfield, P., Carini, D. J., Lee, R. J., Wexler, R. R., Saye, J. A. and Smith, R. D. : Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol. Rev. 45, 205 (1993).
11 Sever, P. S., Gradman, A. H. and Azizi, M. : Managing cardiovascular and renal risk: the potential of direct renin inhibition. J. Renin Angiotensin Aldosterone Syst. 10, 65 (2009).   DOI   ScienceOn
12 Williams, G. H. : Converting-enzyme inhibitors in the treatment of hypertension. N. Engl. J. Med. 319, 1517 (1988).   DOI   ScienceOn
13 Coulter, D. M. and Edwards, I. R. : Cough associated with captopril and enalapril. Br. Med. J. (Clin. Res. Ed.) 294, 1521 (1987).   DOI
14 Roberts, J. R. and Wuerz, R. C. : Clinical characteristics of angiotensin-converting enzyme inhibitor-induced angioedema. Ann. Emerg. Med. 20, 555 (1991).   DOI   ScienceOn
15 Wong, P. C., Price, W. A., Jr., Chiu, A. T., Duncia, J. V., Carini, D. J., Wexler, R. R., Johnson, A. L. and Timmermans, P. B. : Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent. J. Pharmacol. Exp. Ther. 255, 211 (1990).
16 Cheng, Y. and Prusoff, W. H. : Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22, 3099 (1973).   DOI   ScienceOn
17 Wienen, W., Hauel, N., Van Meel, J. C., Narr, B., Ries, U. and Entzeroth, M. : Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277. Br. J. Pharmacol. 110, 245 (1993).   DOI   ScienceOn
18 Hilditch, A., Hunt, A. A., Travers, A., Polley, J., Drew, G. M., Middlemiss, D., Judd, D. B., Ross, B. C. and Robertson, M. J. : Pharmacological effects of GR138950, a novel angiotensin AT1 receptor antagonist. J. Pharmacol. Exp. Ther. 272, 750 (1995).
19 Panek, R. L., Lu, G. H., Overhiser, R. W., Major, T. C., Hodges, J. C. and Taylor, D. G. : Functional studies but not receptor binding can distinguish surmountable from insurmountable AT1 antagonism. J. Pharmacol. Exp. Ther. 273, 753 (1995).
20 Timmermans, P. B. and Smith, R. D. : Angiotensin II receptor subtypes: selective antagonists and functional correlates. Eur. Heart J. 15 Suppl D, 79 (1994).   DOI   ScienceOn
21 Bond, R. A., Ornstein, A. G. and Clarke, D. E. : Unsurmountable antagonism to 5-hydroxytryptamine in rat kidney results from pseudoirreversible inhibition rather than multiple receptors or allosteric receptor modulation. J. Pharmacol. Exp. Ther. 249, 401 (1989).
22 Lee, S. : Characterization of angiotensin II antagonism displayed by KR-31081, a novel nonpeptide AT1 receptor antagonist. J. Korea Academia-Industrial Cooperation Soc. 10, 2997 (2009).   DOI   ScienceOn
23 Timmermans, P. B.: Angiotensin II receptor antagonists: an emerging new class of cardiovascular therapeutics. Hypertension Res. 22, 147 (1999).   DOI